Should I Buy MTVA? MTVA 2026 Analysis

Should You Buy MetaVia Inc (MTVA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

2.360

1 Day change

0.85%

52 Week Range

23.100

Analysis Updated At

2026/01/26

MetaVia Inc (MTVA) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock exhibits weak financial performance, bearish technical indicators, and lacks positive catalysts or significant trading signals. Additionally, there is no recent news or influential trading activity to support a bullish outlook.

Technical Analysis

The technical indicators for MTVA are bearish. The MACD is below 0 and negatively contracting, indicating a downtrend. The RSI is at 10.55, which signals the stock is oversold, but this alone does not confirm a reversal. The moving averages (SMA_200 > SMA_20 > SMA_5) also suggest a bearish trend. Key support levels are far below the current price, and resistance levels are significantly higher, indicating limited upward momentum.

Options Data

Positive Catalysts

NULL identified. No recent news, trading activity, or influential figure involvement to indicate positive sentiment.

Neutral/Negative Catalysts

The stock has an 80% chance of declining in the next day (-2.48%), week (-0.29%), and month (-5.93%). Financial performance shows a significant decline in net income (-40.25% YoY) and EPS (-75.04% YoY). Technical indicators are bearish, and there are no hedge fund or insider trading trends to support a bullish case.

Financial Performance

In Q3 2025, MetaVia Inc reported zero revenue growth (0.00% YoY), a net income drop of -40.25% YoY to -$3,377,000, and a significant EPS decline of -75.04% YoY to -1.52. Gross margin remained at 0, with no improvement.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on analyst ratings or price target changes is available for MetaVia Inc.

2 Analyst Rating

Wall Street analysts forecast MTVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MTVA is 47.5 USD with a low forecast of 40 USD and a high forecast of 55 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.340

Low

Averages

47.5

High

Current: 2.340

Low

Averages

47.5

High

H.C. Wainwright

Andrew Fein

initiated

$12

AI Analysis

2025-09-04

Reason

H.C. Wainwright

Andrew Fein

Price Target

$12

AI Analysis

2025-09-04

initiated

Reason

H.C. Wainwright analyst Andrew Fein assumed coverage of MetaVia with a Buy rating and $12 price target. The firm says Metavia offers a \"compelling opportunity\" in the metabolic disease space based on its two \"differentiated\" pipeline programs.

Maxim

Jason McCarthy

Buy

downgrade

$6 -> $3

2025-05-19

Reason

Maxim

Jason McCarthy

Price Target

$6 -> $3

2025-05-19

downgrade

Buy

Reason

Maxim analyst Jason McCarthy lowered the firm's price target on MetaVia to $3 from $6 and keeps a Buy rating on the shares. The firm cites the company's Q1 results, cash update, and its recent $10M financing in adjusting its model, though it remains positive on MetaVia's obesity (DA-1726) and MASH (DA-1241) treatment opportunities, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MTVA

Unlock Now

MTVA Should I Buy

MTVA Should I Buy

Should You Buy MetaVia Inc (MTVA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch